Cancer vaccines: a revolution underway?

By Ana Espino | Published on January 7, 2026 | 3 min read


Cancer remains one of the leading causes of death worldwide. Despite major therapeutic advances (immunotherapy, targeted therapies), many cancers resist treatment or relapse. One key limitation of current approaches is their inability to induce durable immune memory against tumor cells, which can evade immune surveillance.  

Therapeutic cancer vaccines aim to stimulate a specific immune response against tumor antigens. Their development faces several challenges: tumor heterogeneity, immunosuppression within the tumor microenvironment, selection of relevant target antigens, and identification of the optimal vaccine platform. In this context, this review set out to examine the main vaccine platforms under development (peptides, dendritic cells, DNA/mRNA, viral vectors, nanoparticles) and to summarize recent progress in design, efficacy, and clinical outcomes.  

Which vaccines truly deliver on their promises?  

This review is based on a structured narrative analysis of recent scientific literature, including preclinical and clinical studies across multiple therapeutic cancer vaccine platforms. The authors compared mechanisms of action, advantages, limitations, and available clinical results for the main technologies currently being developed or evaluated.  

The findings highlight a wide diversity of approaches. Peptide-based vaccines, while relatively straightforward to manufacture, often show limited immunogenicity. Dendritic cell vaccines enable efficient antigen presentation but require complex, individualized manufacturing procedures, which restricts scalability and accessibility. DNA and messenger RNA vaccines offer notable flexibility and enable rapid development of personalized formulations targeting tumor-specific neoantigens. Several clinical trials (in melanoma, glioblastoma, and pancreatic cancer) report robust immune responses, sometimes with survival benefits.  

Other technologies are also emerging. Viral-vector and nanoparticle-based vaccines can improve targeting of antigen-presenting cells and enhance stability of vaccine components. Finally, combining these vaccines with potent adjuvants or immune checkpoint inhibitors appears to strengthen clinical efficacy.  

Toward personalized immunotherapy?  

Cancers remain complex and treatment-resistant, in part due to their ability to escape immune control. A central challenge is to induce an effective and durable immune response that targets tumor cells without harming healthy tissues. Against this backdrop, the aim of this review was to take stock of available and emerging vaccine platforms, assessing their therapeutic potential, mechanisms of action, and observed clinical results.  

These findings underscore the growing role of mRNA vaccines, viral vectors, and nanoparticles in the personalization of immunotherapy. However, limitations remain and justify further research: large-scale clinical trials, improved patient stratification based on immunological profiles, and identification of predictive biomarkers of response. There is also a need to standardize protocols, optimize combination strategies (vaccines + immunomodulators), and explore neoadjuvant or preventive approaches—especially in cancers linked to oncogenic viruses such as HPV or EBV.

Read next: Vaccinate better, vaccinate more?